PharmaSGP SE plans to redeem own shares – conditions for squeeze-out under conversion law are met Gräfelfing, June 18, 2025 – PharmaSGP SE (ISIN: DE000A2P4LJ5) currently holds treasury shares representing approximately 4.06% of its share capital as a result of last year's share buyback. In order to make optimal use of the new authorization to acqu [ … ]

Publication of inside information pursuant to Art. 17 para. 1 of Regulation (EU) 596/2014   Ad-hoc Notification PharmaSGP Holding SE: Conclusion of a delisting agreement and announcement of a delisting tender offer by FUTRUE GmbH Gräfelfing, June 10, 2025. Today, PharmaSGP Holding SE (ISIN DE000A2P4LJ5 / WKN A2P4LJ) (“PharmaSGP”) entered into a [ … ]

EQS-WpÜG: Futrue GmbH / Tender Offer Tender Offer / Target company: Pharma SGP Holding SE; Bidder: Futrue GmbH 10.06.2025 / 08:35 CET/CEST Dissemination of an announcement according to the German Securities Acquisition and Takeover Act (WpÜG), transmitted by EQS News - a service of EQS Group. The bidder is solely responsible for the cont [ … ]

PharmaSGP continues its growth course in 2025 Gräfelfing, May 15, 2025 – The German OTC pharmaceutical company PharmaSGP Holding SE has made a successful start to 2025, achieving a 10.8% increase in revenues to €33.5 million in the first quarter based on preliminary, unaudited figures (prior-year quarter: €30.2 million). Compared to the previous y [ … ]

PharmaSGP with significant increase in revenues and EBITDA in 2024 Gräfelfing, April 15, 2025 – Based on preliminary, unaudited figures, the German OTC pharmaceutical company PharmaSGP Holding SE significantly increased its revenues from 2023 by 17.5% to € 118.8 million in the 2024 financial year. The sole driver of the positive business developme [ … ]